MENU
Aim higher

XTN_NAN_LDN-CardioPredict

Human stem cell cardiomyocyte assays and screening platforms for predicting cardiac safety risk

We will leverage partner expertise in cardiac safety testing (XTN), stem cell cardiomyocytes (LDN) and screening platforms (NAN) to develop translational safety assays to predict human cardiac risk. We will deliver optimised human stem cell cardiomyocytes and phenotypic assays using the latest generation of screening platforms to meet future market and regulatory requirements for in vitro cardiac safety data on drug development candidates that reliably predicts their clinical cardiac risk.
Acronym: 
XTN_NAN_LDN-CardioPredict
Project ID: 
9 527
Ranking: 
21
Cut-off: 
2
Start date: 
01-06-2015
Project Duration: 
27months
Project costs: 
2 235 660.00€
Technological Area: 
In vitro Testing, Trials
Market Area: 
Other Biotechnology / Molecular technology